Ocata Therapeutics Inc fka OCAT

[rumper]

The SlowBall Treatment Is Increasing Value Of Ocata

If Ocats is getting FDA fast track,
what the heck is the slow track?

After a certain amount of time, people
will wake up and notice the bureaucrats
dragging their feet. Then there are inquiries,
and FBI people, and firings.
Then your education, and all that time, is worthless.

And meanwhile, more people have discovered Ocata.

Phase 1 accidentally showed a little too much
of what RPE therapy can do.

People will eventually decode the weasel words,
"efficacy signal" into IT WORKS.

Phase 1 halted macular degeneration.
And a halted dry form macular degeneration,
prevents wet form macular degeneration.

Wet macular degeneration is usually preceded by the dry form of the disease. This wet form occurs when the Bruch’s membrane begins to break down,
usually near drusen deposits, and new blood vessels grow. This growth is called neovascularization. These vessels are very fragile and can leak fluid and blood, resulting in scarring of the macula and the potential for rapid, severe damage.

http://www.brightfocus.org/docs/fact-sheets-in-pdf-format/macular_degeneration_frequently_asked_questions.pdf

The slow ball leads to a pricey buyout for Ocata.
And fast track leads to a new Ocata behemoth.
Tough, tough cookies.

Ocata Could Potentially Cure 90% Of Legal Blindness

Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness.

http://www.brightfocus.org/macular/about/understanding/facts.html

Ocata's Share Count is: 35,667,442

And 1 billion of market cap represents
a share price of $28 dollars.

This is the likely starting point of a buyout.

We'll see.

Tiny, Tiny, Share Count!
-tiny is more better

100% Safe Phase 1 Success
-Don't Worry Speedracer

Strong Unexpected Efficacy Signal
-It Works

Patents Galore
-Galore is Good